Fly News Breaks for February 28, 2020
Feb 28, 2020 | 08:02 EDT
Intellia Therapeutics is making progress in in-vivo editing and ex-vivo engineered T-cells, Oppenheimer analyst Silvan Tuerkcan tells investors in a research note following the company's Q4 results. The NTLA-2001 Investigational New Drug submission remains on track for transthyretin amyloidosis in mid-2020 and preparations are ongoing, adds the analyst. Tuerkcan, however, views Intellia as fairly valued at current levels and keeps a Perform rating on the shares.
News For NTLA From the Last 2 Days
There are no results for your query NTLA